ArticleClinical journal of the American Society of Nephrology : CJASN2026
Validation of the Predicting Risk of Cardiovascular Disease EVENTs (PREVENT) Equations in a CKD Population: A Nationwide Veterans Analysis.
Article in Clinical journal of the American Society of Nephrology : CJASN, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
key pointsThe Predicting Risk of Cardiovascular Disease EVENTs equations optimize risk prediction in the modern era of increasing cardiovascular kidney metabolic disease prevalence. Risk prediction is most helpful to intensify therapy in those with less advanced kidney disease. In those with advanced kidney disease, risk indices provide little utility beyond biomarkers alone such as eGFR and albuminuria.
backgroundCardiovascular kidney metabolic syndrome is a growing public health problem and leading cause of cardiovascular mortality. We evaluated model performance of the American Heart Association Predicting Risk of Cardiovascular Disease EVENTs (PREVENT) equations in a large single health system population in patients with CKD and across strata of kidney function and compared findings where applicable to those of the pooled cohort equations (PCE).
methodsVeterans with eGFR measurements were divided into three groups: eGFR ≥60, eGFR 30-59, and eGFR 15-29. We assessed the base PREVENT equations for total cardiovascular disease (CVD), atherosclerotic CVD (ASCVD), and heart failure as well as add-on equations using albuminuria. Accuracy of equations was assessed with c-index as a measure of discrimination and calibration curve slopes as a measure of calibration.
resultsOverall c-index was 0.651 for PREVENT-CVD, 0.633 for PREVENT-ASCVD, and 0.673 for PREVENT-heart failure. Discrimination of PREVENT-ASCVD was modestly greater than that of PCE (0.633 versus 0.629, respectively). For all three base PREVENT equations, discrimination declined with advancing kidney disease. Overall calibration slopes for the PREVENT equations ranged from 0.78 to 1.27. PREVENT-ASCVD had superior calibration compared to PCE with a calibration slope of 1.27 and 0.53, respectively. In those with urine albumin to creatinine ratio (UACR) measurements, discrimination of UACR add-on equations improved from base equations in those with less advanced kidney disease (c-index 0.624 for PREVENT-CVD UACR versus 0.607 for PREVENT-CVD base equation in those with eGFR ≥60, and c-index 0.586 for PREVENT-CVD UACR versus 0.563 for PREVENT-CVD base equation in those with eGFR 30-59). This trend was similar for the PREVENT-ASCVD and PREVENT-heart failure UACR add-on equations.
conclusionsIn a CKD population, the PREVENT equations perform best in those less advanced stages of CKD and cardiovascular kidney metabolic, presenting an opportunity to apply disease-preventing and disease-modifying therapeutics in a timely manner.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.